A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5
sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with
dose escalation to weekly dosing available for participants not receiving concomitant
disease-modifying antirheumatic drugs (DMARDs) who did not achieve American College of
Rheumatology 20 (ACR20) criteria after 12 weeks of treatment. Efficacy and safety
measurements were performed throughout the study.